Urologic Care for the APP Industry Sponsored Lunch (Non-CME)

A Non-CME Lunch Symposium supported by Astellas Pharma US, Inc. and Pfizer Oncology for APPs: Treatment Intensification with XTANDI (Enzalutamide) for Patients with Metastatic Castration-Sensitive Prostate Cancer & Nonmetastatic Castration-Sensitive Prostate Cancer with Biochemical Recurrence at High Risk for Metastasis.